Compare Natera Inc. Common Stock (NTRA) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Walmart Stores Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Walmart Stores Inc trades at $116.99 (market cap $890.80B). The key difference: Walmart Stores Inc is far larger — about 15.6× Natera Inc. Common Stock's market cap, and Walmart Stores Inc pays a 0.88% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Walmart Stores Inc for 101 Days on average.
| NTRA | WMT | |
|---|---|---|
Market Cap | $57.03B | $890.80B |
Volume | 1,131,157 | 17,493,315 |
Sector | Health | Consumer Staples |
52-Week High | $425.64 | $134.20 |
52-Week Low | $179.42 | $100.61 |
Typical Hold Time | 0 Days | 101 Days |
Enterprise Value | $56.18B | $953.03B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Walmart (WMT) trades at $113.08, up 1.55% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $680.99B in 2025, with net income reaching $19.44B, and the company has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion in AI capabilities, e-commerce growth exceeding 50%, and a new Medicare Advantage partnership, signaling strategic initiatives to bolster market share.
The outlook for WMT is positive, supported by robust earnings growth, analyst consensus favoring buys (71%), and a price target of $128.84 implying ~14% upside. Key risks include elevated valuation multiples (P/E 40.68) and rising operational costs, but the company's scale and digital investments provide a competitive edge. Investors should weigh growth prospects against cost pressures and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
